Tony Zook is recorded as Chairman at Neogenomics Inc (NEO) since January 4, 2027 and CEO and Board Member at Neogenomics Inc (NEO). The newest filing on record that lists Tony Zook as CEO and Board Member at Neogenomics Inc (NEO) is dated April 6, 2026. Neogenomics Inc reported in an 8-K filed October 5, 2026 that Tony Zook was appointed Executive Chairman, effective January 4, 2027. Neogenomics Inc reported in an 8-K filed January 10, 2025 that Tony Zook was appointed Chief Executive Officer, effective April 1, 2025. Neogenomics Inc reported in an 8-K filed June 29, 2023 that Tony Zook was appointed directors, effective June 26, 2023. The proxy statement of Neogenomics Inc reports total compensation of $9,127,092 for Tony Zook in fiscal 2025, including a base salary of $601,539. Disclosed compensation is on record for 3 fiscal years. Tony Zook has spoken on 5 earnings calls and 3 other investor events across 1 company, most recently for Neogenomics Inc on October 28, 2026. Neogenomics Inc is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Neogenomics Inc includes Chris Smith (CEO and Board Member), Christopher Smith (CEO and Board Member), Warren Stone (CEO, COO and Board Member) and 7 others.
“the Board also approved the executive transition of Tony Zook, the Company's current Chief Executive Officer and a member of the Board, to the role of Executive Chairman, effective as of January 4, 2027.”
Neogenomics Inc Form 8-K, filed October 5, 2026
· Read the filing
“On January 10, 2025, the Company announced the appointment of Tony Zook to replace Mr. Smith as Chief Executive Officer effective April 1, 2025.”
Neogenomics Inc Form 8-K, filed January 10, 2025
· Read the filing
Tony Zook on recent calls
“We're excited to report another strong quarter, which shows we have the right strategy in place, the right team to execute it, and we're delivering consistent results because of this.”
“I guess first, you know, neogenomics, pure play oncology, I think is an important factor. We remain focused in oncology because we think it allows us to better understand and serve our customers.”
“Well, thank you, Andrew, and welcome to the team. We're very pleased to have you join us. And good afternoon, everyone. At NeoGenomics, our leading 25% market share across hematology diagnostics and therapy selection make us a trusted provider of oncology testing solutions for pathologists, oncologists, and patients.”
“Now I would like to open it up to the stockholder questions and comments. Please note, we'll attempt to answer as many questions as time allows, but only questions that are germane to the meeting will be addressed.”
